Companies: 10,795·Total market cap: $144.5T
Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

LGNDNASDAQHealthcare● Active
$237.80
+$0.80(+0.34%)
Market Cap$4.8B
P/E Ratio
52W High$247.38
52W Low$102.5

Ligand Pharmaceuticals Incorporated (LGND) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

lgnd · stock forecast · 17 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 17 Wall Street analysts in the past 3 months

SellBuy

Buy

17 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
12
Hold
4
Sell
1
Strong Sell
0
Total: 17 · Buy rate: 70.6%

12-Month Price Target

High

$289

Consensus

$268

+12.8% upside

Low

$252

Median: $265 · Last Close: $237.41

The Ligand Pharmaceuticals Incorporated (LGND) analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month LGND price target is $267.75, representing +12.8% upside from the current price of $237.41.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $268 (12.8%)

Consensus Target

$267.75

12.8% upside

High Target

$289

21.7%

Low Target

$252

6.1%

Current Price

$237.41

as of today

Based on analyst price targets, the LGND stock price prediction for the next 12 months ranges from $252 to $289. The consensus LGND price forecast of $267.75 implies 12.8% upside from the current price of $237.41.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$243.172.42%

1-day model range: $241.95–$244.38. Peak: $244.38 (+2.42%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$427+80.0%
2028$632+166.4%
2029$815+243.1%
2030$955+302.4%
2031+344.1%
Confidence:MediumCapped at 80% annual limit

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%0%7%
13Buy
0Neutral
1Sell
RSI (14)85.2Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · LGND · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$235.50BUY
MA 10$234.51BUY
MA 20$226.30BUY
MA 50$221.84BUY
MA 100$209.93BUY
MA 200$197.56BUY
Current $LGND · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$235.62BUY
EMA 10$233.09BUY
EMA 20$229.48BUY
EMA 50$222.32BUY
EMA 100$212.59BUY
EMA 200$194.60BUY
Current $LGND · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
RBC Capital2026-05-08
Maintains
OutperformOutperform
HC Wainwright & Co.2026-04-30
Maintains
BuyBuy
RBC Capital2026-04-28
Maintains
OutperformOutperform
Citigroup2026-04-15
Maintains
BuyBuy
HC Wainwright & Co.2026-04-14
Maintains
BuyBuy
Citigroup2026-03-24
Maintains
BuyBuy
Oppenheimer2026-02-27
Maintains
OutperformOutperform
HC Wainwright & Co.2026-02-24
Maintains
BuyBuy
RBC Capital2025-12-10
Maintains
OutperformOutperform
Stifel2025-12-10
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Ligand Pharmaceuticals Incorporated (LGND) stock. Of the recent 98 rating actions, 2 were upgrades and 8 were downgrades. 17 analysts currently cover LGND.

Analyst Recommendation Trends

Buy ratings514
Hold ratings00
Sell ratings00

LGND analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$285M

↓ 34.3% YoY

Revenue Next Year

$363M

↑ 27.3% YoY

EPS This Year

$9.06

EPS Next Year

$11.13

↑ 22.9% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast LGND EPS of $9.06 for the current fiscal year, based on estimates from 6 analysts. The LGND revenue forecast is $285M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The LGND stock forecast is supported by two independent data sources: analyst consensus ratings from 17 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LGND price target is $267.75 (+12.8% upside), with an analyst consensus of Buy.

The LGND short-term stock prediction for tomorrow is $243.17 (+2.42%). The LGND stock price prediction for 2027 estimates an average of $427. The LGND stock prediction for 2030 projects a range of $903–$1008.

Ligand Pharmaceuticals Incorporated trades on NASDAQ under the ticker LGND. The LGND stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

LGND forecast · 8 questions

According to 17 Wall Street analysts, the average 12-month LGND price target is $267.75, with a high forecast of $289.00 and a low of $252.00. The median price target is shown in the chart above when available. This implies +12.8% potential upside from the current price of $237.41.

LGND price targetWhat is LGND price targetLGND analyst price targetLGND 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.